The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Torgunrud, A., Lund-Andersen, C., Davidson, B., Marcussen, I. K. N., Larsen, S. G., Dagenborg, V., & Flatmark, K. (2025) · Pleura and Peritoneum · doi:10.1515/pp-2025-0034
Revealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung AdenocarcinomaPreprint
Wirth, C., Zhang, T., Díaz‐Gay, M., Steele, C. D., Hoang, P. H., Yang, Y., Khandekar, A., Zhao, W., Sang, J., Leduc, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695410
Barua, A., Kundu, S. T., Garza, S., Fradette, J. J., Choudhary, B. S., Peng, D. H., Diao, L., Wang, J., & Gibbons, D. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.696060
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Zhang, L., Bolomsky, A., Al‐Odat, O. S., VanWinkle, C. K., Battle, A., Chakraborty, P., Holewinski, R. J., Andrésson, Þ., Häupl, B., Oellerich, T., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0028 · Cited by 1
Vinot, C., Ferté, C., Gaboriaud, T., Minvielle-Sebastia, A., Dubois, A., Schwob, R., Mallah, S., Pajiep, M., Alliot, J., Ferreira, A., et al. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100660
Htoo, A., Malenie, R., & Xing, J. (2026) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2026.01.002
The current status of medicine development for precision therapy and diagnosis targeting KRASG12C
Zhang, C., Wang, F., & Tian, G.-L. (2026) · Biophysics Reports · doi:10.52601/bpr.2026.250060
KRAS Mutations in Circulating Tumor DNA for Lung Cancer Diagnosis: A Comprehensive Meta-Analysis
Buszka, K., Gąsiorowski, Ł., Dompé, C., Szulta, A., Nowicki, M. P., Kolecka-Bednarczyk, A., & Budna-Tukan, J. (2026) · Cancers · doi:10.3390/cancers18020250
Clinical Applications of Liquid Biopsy
Kim, S. H., & Kim, Y. (2026) · Springer eBooks · doi:10.1007/978-981-99-4418-7_5
Liu, J., Tang, J., Chen, H., Zhang, L., Li, G., Zhang, F., Chen, S., & Yu, J. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00349
Belafriekh, A., Laoud, A., Alaqarbeh, M., Zafar, I., Elmchichi, L., & Shafiq, S. (2026) · ChemistrySelect · doi:10.1002/slct.202505932
Targeted Therapy-Induced Chromosomal Instability Dictates Mitotic Dependency on Aurora Kinase APreprint
Li, C., Nangia, V., Vieira, M. D., Nimbalkar, A., Graser, C. J., Chang, J. B., Syed, M. U., Shen, Y., Koranne, R., Zou, L., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.01.22.701085
Actionable subgroups (I): RAS (KRAS G12C) and BRAF V600E
Alonso-Orduña, V., Tobeña, M., & Marqués, E. P. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00134
Tian, L., Han, Q., Qiao, Y., Chu, P., & Chen, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02703
Schulte, A., & Andrechek, E. R. (2026) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-026-09599-7 · Cited by 1
Medical Management of Musculoskeletal Metastasis from Lung Cancer
Stoel, G. W., Geiger, E. J., & Rodríguez, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-09498-8_27
Noordhof, A. L., Asmara, O. D., de Jong, K., Gijtenbeek, R. G. P., Huitema, Y. M., van Vollenhoven, F. H. M., Venmans, B. J. W., Hendriks, L. E. L., & van Geffen, W. H. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016054
Su, Y., Wang, C., Sun, L., Jin, F., Wang, X., Wang, S., & Wang, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1795432
Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies
Jones, D. T., Nanda, R. K., Hussain, A. A., Hattin, R., Myat, Y. M., Thawani, R., Cetnar, J. P., Shanshal, M., Thein, K. Z., & Kummar, S. (2026) · Cancers · doi:10.3390/cancers18050856
Spagnuolo, A., Spagnoletti, I., Nuccio, E., & Gridelli, C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2636928
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors
Kanemura, H., Takehara, T., Maenishi, O., Tomida, S., Iwawaki, N., Kunimasa, K., Nakayama, T., Watanabe, S., Suzuki, S., Sakai, K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0489
MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy
Carpenter, C., Simmons, N., Davis, W. J. H., Thompson, M., van Zandwijk, N., Drummond, C. J., & Reid, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062701
Chen, R., Ma, Z., Yuan, M., Qian, K., & Zhu, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1784222
E2A selectively regulates TGF‐β–induced apoptosis in KRAS ‐mutant non‐small cell lung cancer
Chuikov, S., Katkam, S. K., Wang, Z., & Keshamouni, V. G. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70236
Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours
Clemente‐Suárez, V. J., Olivares, R., Yáñez-Sepúlveda, R., Guzmán-Muñóz, E., & Rodríguez, A. M. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04319-3
Cancer biology and the principles of targeted cancer drug discovery
Davies, A., Jones, G., Krishnan, S., Krishnamoorthy, M., Maruggi, M., Kaneda, M., & Marjon, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00035-2
Arriola‐Montenegro, J., Mekraksakit, P., Albadri, S. T., & Suarez, M. L. G. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100018
Vicent, S., Welch, C., Novoa, G., Vasquez-Valencia, C., Macaya, I., Jimenez-Alonso, J. J., Subrizio, A., Lagos, A. F., Llorente, S., Jimenez, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9085811/v1
Desachy, G., Köchert, K., Krämer, N., Kubiak, R., & Biomarkers European Special Interest Group (2026) · Communications Medicine · doi:10.1038/s43856-026-01524-7
Fatty acid scavenging enables cancer escape from KRAS inhibitionPreprint
Yuan, Z., Lin, B., Wang, C., Miao, Y., Zhang, D., Meng, Z., Wang, G., Lowy, A. M., Karin, M., Yang, F. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.01.715565
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127
Innovative targeted therapies for mosaic RAS-related vascular malformations
Morin, G. (2024) · theses.fr (ABES) · doi:10.70675/88882e5fz1bf9z4dbezae13zba4200ee9598
Wang, J., Jiang, L.-L., Wang, M., & Li, Y.-L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s600434 · Cited by 1
MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
Laurent, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/e7695737z26a3z4747zafafzb19e3e74372b
Toxicités cardiovasculaires des principales thérapies ciblées orales dans les tumeurs solides
Nannini, S., Droesch, C., Schultz, É., & Moinard‐Butot, F. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.02.014
Unlocking drug sensitivity in KRAS
MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279
Shpeer, E. L., Zarubina, K. I., Kulikova, E. A., & Gusev, A. B. (2026) · Ведомости Научного центра экспертизы средств медицинского применения · doi:10.30895/1991-2919-2026-856
Bradová, M., Slavík, P., Vaněček, T., Martínek, P., Grossmann, P., Kormunda, S., Behenska, K., Svatoň, M., Pešek, M., Jirásek, T., et al. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04526-x
Wu, S., Niu, J., Chen, X., Li, J., Tang, Q., Yang, Z., & Gao, S. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70670
He, L., Sun, Y., Ma, B., Lang, G., Wen, J., Blumenschein, G. B., & Ma, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772428
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Cancers · doi:10.3390/cancers18091367
Kazakov, A. M., Gordiev, M. G., Лактионов, К. К., Kruteleva, S. Y., & Tkacheva, D. D. (2026) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2026-25-1-19-27
Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib
Li, B. C. W., Li, J. J. X., Tse, K. Y., Lu, H., & Chan, K. K. L. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01077
Wu, Y. H., Zhang, L., Gui, J., Wang, J., Long, X., Lan, X., Lin, Y., & Cao, W. (2026) · Journal of Nuclear Medicine and Molecular Imaging · doi:10.65457/jnmmi-2026-0009
Andrade, A., Mureb, M., Karaman, N., Liu, C., Sabari, J. K., Veluswamy, R. R., Bernstein, K., Donahue, B. R., Cooper, B. T., & Kondziolka, D. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05547-x
Self-citationComplications following small-molecule inhibitors for non-small cell lung cancer
Kamali, C., & Ekman, S. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2665836
Khan, U. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.723102
Davis, W. J. H., Thompson, M., Farry, S. M., McKinney, C., Gimenez, G., Hatley, M. E., Kumar, R., Rodger, E. J., Chatterjee, A., Diermeier, S. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723110
Chiyoda, A., Matsuo, A., Yamano, T., & Tanada, M. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00122 · Cited by 1
Li, R., Liu, Y., & Shanshan, L. (2026) · Research Square · doi:10.21203/rs.3.rs-9689757/v1
Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma
Wilson, H. P., Stefanski, C. D., Caksa, S., Mersky, G. L., Varney, S. D., Haj, J. I., Erkes, D. A., Purwin, T. J., Chua, V., & Aplin, A. E. (2026) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70090
Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications
Saga, A., Li, G., Tanaka, T., Kaneko, M. K., Suzuki, H., & Kato, Y. (2026) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1177/21679436261450334
Wang, X., & Yu, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1851178
Aung, W. Y., Neumann, M., Wang, K. H., Chukkalore, D., Morales, J., & Seetharamu, N. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01315
Molecular Analysis of EBUS-TBNA Samples for Nodal Staging in Non-Small Cell Lung Cancer
Ehab, A., Benabdallah, N., & Darwiche, K. (2026) · Cancers · doi:10.3390/cancers18111797
Torrini, C., Nayyar, N., Wojtkiewicz, G. R., Giobbie‐Hurder, A., de Sauvage, M. A., Migliarese, C., Summers, E., Ijad, N., Yamazawa, E., Zhang, B. S., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag107
Üveges, E., Gaál, A., Szakács, G., Bakos, É., Streli, C., Kregsamer, P., Baranyi, M., Hegedűs, B., & Szoboszlai, N. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05171-w
Pisapia, P., Iaccarino, A., Luca, C. D., Pepe, F., Russo, G., Nacchio, M., Giovanni, D. D., Cozzolino, D., Conticelli, F., Palumbo, L., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04374-w
Discovery of TCR-like antibodies to the KRAS G12D neoantigen via in silico-in vitro workflow
Ahn, S., Oh, T.-S., Suh, S., Jeon, J. H., Lah, S., Ryu, K., Choi, S., Kim, H., Lee, E. G., Lee, H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.032
Tomaschko, M., Ng, K., Moore, C. L., Pillsbury, C. E., Rana, S., Campbell, J., Mukherjee, S., Mikolajczak, A., Anastasiou, P., de Castro, A., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5693
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Jain, A., Rosell, R., Dharmashekara, C., Shreevatsa, B., González-Cao, M., Shivakumar, A., Kollur, S. P., Prasad, A., Shivamallu, C., & Prasad, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05533-0
Kızıl, H. E., Ekíncíoğlu, Y., Özkan, E. H., Güllü, E., & Nartop, D. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00785-4
Enabling Process Development of Tetracyclic Quinolines for Brain-Penetrating KRAS G12C Inhibitors
Deng, L., Young, I. S., Deichert, J. A., & Han, C. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00167
Wang, D., Xiao, M., Zhou, K., Yang, P., Huang, X., Miao, R., Fan, J., Zhang, X., & Wang, S. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113262
Ha, G., Chacha, L. D., Coe, L., Yanis, S., Faith, I., Vasquez, F., Duodu, J., Vimolratana, M., Chudgar, N. P., Cheng, H., et al. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-026-03050-7
M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLSPreprint
Takamori, S., Haratake, N., Nonaka, K., Moriya, M., Bhattacharya, A., Takenaka, T., Yoshizumi, T., Long, M. D., & Kufe, D. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.20.733526
Valencia-Sama, I., Kee, L., Weiss, A., Hayes, M. N., Ohh, M., & Irwin, M. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.24.734371
RAF1 scaffold integrity shapes chemogenetic degradation outcomes in KRAS-driven lung cancerPreprint
Ovejero, L. D. L. P., Domostegui, A., García-Pérez, I. M., Aizpurua, G., Lomba-Riego, L., Ximénez‐Embún, P., Mayor‐Ruiz, C., Barbacid, M., & García‐Alonso, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.23.733960
Therapeutic inhibition of RAS in non-small cell lung cancer
Nichols, K. B., & Herzberg, B. O. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817943
Biochemistry at scale: Seeing both the forest and the trees
Harry, S. A., Vasavda, C., Wahida, A., Stevens, R., Singh, H., Goldman, I. D., Chabner, B. A., & Bar‐Peled, L. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.05.005
Lu, D., Osgood, T., Ma, S., Zhang, H., Kanke, M., Tan, J. A., Paudel, S. N., Zhou, H., Estrada, J., Yamawaki, T., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0794 · Cited by 1
Abdelsamia, M., Li, Y., Eastwood, D., & Rabinowitz, I. (2026) · Future Oncology · doi:10.1080/14796694.2026.2699426
Aly, A. S., Yacoub, Z., & Yacoub, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10252473/v1
Yan, Y., Zheng, L., Wang, H., Sun, L., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848431
Research on Thoracic Cancer: Lung Cancer
Calkins, K., Jiang, T., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_17
Din, S. M. U., Kiamos, A., Ali, S., Mehta, M. M., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146251
Kawczak, P., Kawczak, K., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145521
Azvudine enhances durable tumor control with sotorasib in a CT26-mKRAS G12C syngeneic model
Jia, L., Qin, Z., & Li, P. (2026) · Academia oncology. · doi:10.20935/acadonco8419
Zhu, X., Xue, S., Wang, W., Zhang, X., Cui, Z., Chen, Z. F., & Debnath, S. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c01293
KRAS-mutated Non–Small Cell Lung Cancer
Saadany, T. E., Aeschlimann, N., & Sacher, A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000842
Comparing Real-Time PCR and Amplicon-Based NGS for Routine EGFR Liquid Biopsy Profiling
Bragadin, A. B., Tosello, V., Longo, S., Padovan, A., Baldissin, S., Bianco, P. D., Masetto, E., Callegarin, F., Bonanno, L., Pasello, G., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16152392
Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation
Shen, L., Gao, Y., Song, Z., Wang, Q., Zhou, Q., Lei, Y., Lü, S., & Li, Z. (2026) · BMC Cancer · doi:10.1186/s12885-026-16643-6
ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC
Caumeil, M., Vendrell, J. A., Cabello‐Aguilar, S., Cavaillon, S., Thomas, Q. D., & Solassol, J. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70313
Yuan, B., Zhang, Y., Li, X., Dong, Y., An, X., Jiao, T., Zhang, C., Chen, Y., Shi, J., Wu, S., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03858-1
Sun, Y., Song, M., Ding, W., Liu, Q., Lu, W., Luo, B., Chen, P., Yang, J., Hu, Y., Wen, S., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218773
Primary Tumor Genomics and Patterns of Distant Recurrence in Resected Gastric Cancer
Coffey, M. R., Xu, J., Atri, P., Lambert, K. E., Shimada, S., Walch, H., Stroobant, E. E., Verdone, A. M., Tang, L. H., Shah, S. P., et al. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.3270
Li, X., Guo, Y., & Yang, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108367 · Cited by 1
Salih, R., Sirajudeen, F., & Rahmani, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.030
RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells
Alharbi, S., Merkle, S., Pastura, P. A., McDaniel, C. G., Zaky, G. S., Waters, A. M., & Cras, T. D. L. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71316
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer
Carvalho, G. D. S., Vianna, C. L., Wilheim, A., Santo, M. E., Milagres, R., Small, I. A., & Araujo, L. H. (2026) · BMC Cancer · doi:10.1186/s12885-026-16769-7
Piekarz, J., Picheta, N., Pobideł, J., Gierulska, N., Kłodnicka, K., Januszewski, J., Szklener, K., & Skórzewska, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1916211
Chemical Biology 2025: Highlights From the Ch/Bi145 Course at Caltech
Ashton-Rickardt, G. P., Chung, D. K., Corman, S. A., Gilbert, M. S., Green, Z. B., Hengartner, E. R., Hou, J., Kang, D., Konsler, J. K., Kuleshova, I. D., et al. (2026) · ChemBioChem · doi:10.1002/cbic.70485
Wu, H., Weng, R., Gu, S., Wang, J., Ma, X., Li, J., Tie, X., Huang, C., & Chen, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1916788
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
